SecBot SecBot
8-K ·Filed Feb 26, 2026

NVCR

NovoCure Ltd
MIXED
Impact 7/10
Horizonmonths Processed8mo ago SEC0001645113-26-000018
8-K Item 2.02: Earnings release
Actionable Insight ◆ Mixed

The FDA approval of Optune Pax represents a significant commercial opportunity, but investors should monitor whether the company can improve margins and achieve profitability as it invests heavily in clinical trials (KEYNOTE D58, LUNAR-2) and commercialization. The reinstatement of CMS billing privileges removes a near-term regulatory risk.

DirectionMixed
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$13.75
T+0 close · Feb 26, 2026 · via day close
Latest settled
+30.18%
T+60 · $17.90
Vs SPY
+22.43%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Feb 26 $13.75entry
  2. T+1 · 9mo ago −0.58%α −0.13% · $13.67
  3. T+5 · 9mo ago +3.49%α +4.62% · $14.23
  4. T+20 · 8mo ago −14.47%α −8.07% · $11.76
  5. T+60 · 6mo ago +30.18%α +22.43% · $17.90
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

NovoCure reported 8% year-over-year revenue growth for Q4 and full year 2025, driven by increased active patients on therapy. The company received FDA approval for Optune Pax in locally advanced pancreatic cancer, a key milestone. Despite revenue growth, the company reported a net loss of $24.5 million in Q4 and guided for Adjusted EBITDA between -$20 million and $0 million in 2026 as it continues investing in clinical trials and commercialization.

Key Financial Metrics

Revenue
$655.4M
+8.0% YoY
EPS
$-1.22
Guidance
$675 million - $705 million
maintained
Gross Margin
76%

Key Facts

  • Full year 2025 revenue was $655.4 million, up 8% YoY; Q4 revenue was $174.4 million, also up 8% YoY
  • FDA approved Optune Pax for locally advanced pancreatic cancer in February 2026
  • Q4 2025 net loss was $24.5 million with loss per share of $0.22
  • Gross margin declined to 76% from 79% in prior year due to HFE array rollout, pre-reimbursement NSCLC costs, and tariffs
  • 2026 guidance: revenue of $675M-$705M and Adjusted EBITDA of -$20M to $0M
  • CMS billing privileges were briefly revoked then reinstated retroactively; company expects no revenue impact

Financial Impact

Revenue growth of 8% YoY to $655.4 million in 2025, but continued losses with Q4 net loss of $24.5 million and gross margin compression from 79% to 76%

revenuegross marginnet lossepsadjusted ebitda

Segment Breakdown

SegmentRevenue
Optune Gio$174.4M
Optune Lua$3.5M

Risk Factors

  • Continued gross margin pressure from HFE array rollout and pre-reimbursement costs
  • Heavy R&D spending ($60.9M in Q4, up 19% YoY) delaying path to profitability
  • Dependence on successful clinical trial outcomes and reimbursement approvals for new indications

Market Snapshot

Exchange
Nasdaq

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001645113-26-000018
Document: nvcr-20260226.htm0001645113-26-000018
Document: 0001645113-26-000018-index-headers.html0001645113-26-000018
Document: 0001645113-26-000018-index.html0001645113-26-000018
Document: 0001645113-26-000018.txt0001645113-26-000018

Track record

20 reports on NVCR

Performance horizon

5 of 7 bullish or bearish reports moved the stock their way by T+1. Best: +19.75% at T+20 after the Feb 27, 2026 report. 5 of 7 went positive at some point.

Filters
  1. Nov 12, 20264d ago Insider Cluster Neutral 2/10 Entry $11.83 to $11.30 Now $11.30 −4.48% ▼ −4.48% −2.57% vs SPY
  2. Nov 9, 20267d ago SC 13G/A Neutral 3/10 Entry $11.81 to $11.99 Now $11.30 −4.32% ▲ +1.52% +0.21% vs SPY
  3. Nov 9, 20267d ago 144 Neutral 2/10 Entry $11.81 to $11.99 Now $11.30 −4.32% ▲ +1.52% +0.21% vs SPY
  4. Nov 9, 20267d ago 8-K Bearish 6/10 Entry $12.53 to $11.81 Now $11.30 +9.82% ▲ +5.75% +5.38% vs SPY
  5. Oct 29, 202618d ago 8-K Bullish 6/10 Entry $13.11 to $13.15 Now $11.30 −13.81% ▲ +0.31% +2.08% vs SPY
  6. Oct 1, 20266w ago 8-K Bullish 6/10 Entry $15.92 to $14.94 Now $11.30 −29.02% ▼ −6.16% −6.90% vs SPY
  7. Sep 9, 20269w ago 8-K Neutral 2/10 Entry $15.63 to $15.35 Now $11.30 −27.70% ▼ −1.79% −1.19% vs SPY
  8. Sep 1, 202610w ago 8-K Neutral 3/10 Entry $17.38 to $17.83 Now $11.30 −34.98% ▲ +2.59% +2.15% vs SPY
  9. Jul 23, 202616w ago 8-K Bullish 7/10 Entry $19.99 to $17.65 Now $11.30 −43.47% ▼ −11.71% −11.81% vs SPY
  10. Jun 30, 202619w ago 8-K Bullish 7/10 Entry $15.15 to $15.78 Now $11.30 −25.41% ▲ +4.16% +4.29% vs SPY
Showing 10 of 20

US Market Status

Market Closed · Opens in 9h 21m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Feb 26, 2026